Referenser

  1. Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection. J Allergy Clin Immunol Pract. 2020;8(1):91-101.

  2. Läkemedelsverket. Behandlingsrekommendation: Atopisk dermatit. Uppsala: juni 2023.

  3. Li Y, Li L. Contact Dermatitis: Classifications and Management. Clin Rev Allergy Immunol. 2021;61(3):245-81.

  4. Svenska Sällskapet för Dermatologi och Venereologi (SSDV). Handläggning och behandling av handeksem. SSDV:s rapportserie. 2022(1).

  5. Dall'Oglio F, Nasca MR, Gerbino C, Micali G. An Overview of the Diagnosis and Management of Seborrheic Dermatitis. Clin Cosmet Investig Dermatol. 2022;15:1537-48.

  6. Nazarko L. Diagnosis and treatment of venous eczema. Br J Community Nurs. 2009;14(5):188-94.

  7. Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation. 2014;130(4):333-46.

  8. Robertson L, Lee AJ, Gallagher K, Carmichael SJ, Evans CJ, McKinstry BH, et al. Risk factors for chronic ulceration in patients with varicose veins: a case control study. J Vasc Surg. 2009;49(6):1490-8.

  9. Läkemedelsbehandling av bakteriella hud och mjukdelsinfektioner i öppenvård – behandlingsrekommendation. Information från Läkemedelsverket. 2018;29(3):19-30.

  10. Ward S. Eczema and dry skin in older people: identification and management. Br J Community Nurs. 2005;10(10):453-6.

  11. Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461-98.

  12. Dressler C, Rosumeck S, Nast A. How Much Do We Know about Maintaining Treatment Response after Successful Acne Therapy? Systematic Review on the Efficacy and Safety of Acne Maintenance Therapy. Dermatology. 2016;232(3):371-80.

  13. Nast A, Rosumeck S, Dressler C, Werner RN, Ochsendorf F. Antibiotic resistance in acne. Lancet Infect Dis. 2016;16(7):775-6.

  14. Nast A, Rosumeck S, Erdmann R, Alsharif U, Dressler C, Werner RN. Methods report on the development of the European evidence-based (S3) guideline for the treatment of acne - update 2016. J Eur Acad Dermatol Venereol. 2016;30(8):e1-e28.

  15. Hampton PJ, Berth-Jones J, Duarte Williamson CE, Hay R, Leslie TA, Porter I, et al. British Association of Dermatologists guidelines for the management of people with rosacea 2021. Br J Dermatol. 2021;185(4):725-35.

  16. Eisman S, Sinclair R. Pityriasis rosea. Bmj. 2015;351:h5233.

  17. Zuberbier T, Abdul Latiff AH, Abuzakouk M, Aquilina S, Asero R, Baker D, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77(3):734-66.

  18. Huang AH, Kaffenberger BH, Reich A, Szepietowski JC, Ständer S, Kwatra SG. Pruritus Associated with Commonly Prescribed Medications in a Tertiary Care Center. Medicines (Basel). 2019;6(3).

  19. Kremer AE, Mettang T, Weisshaar E. Non-dermatological Challenges of Chronic Itch. Acta Derm Venereol. 2020;100(2):adv00025.

  20. Pereira MP, Basta S, Moore J, Ständer S. Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need. J Eur Acad Dermatol Venereol. 2018;32(12):2224-9.

  21. Pereira MP, Nau T, Zeidler C, Ständer S. [Chronic prurigo]. Hautarzt. 2018;69(4):321-30. Chronische Prurigo.

  22. Pereira MP, Ständer S. Therapy for pruritus in the elderly: a review of treatment developments. Expert Opin Pharmacother. 2018;19(5):443-50.

  23. Pereira MP, Zeidler C, Storck M, Agelopoulos K, Philipp-Dormston WG, Zink A, et al. Challenges in Clinical Research and Care in Pruritus. Acta Derm Venereol. 2020;100(2):adv00028.

  24. Weisshaar E, Szepietowski JC, Dalgard FJ, Garcovich S, Gieler U, Giménez-Arnau AM, et al. European S2k Guideline on Chronic Pruritus. Acta Derm Venereol. 2019;99(5):469-506.

  25. Chen YE, Tsao H. The skin microbiome: current perspectives and future challenges. J Am Acad Dermatol. 2013;69(1):143-55.

  26. Yamazaki Y, Nakamura Y, Núñez G. Role of the microbiota in skin immunity and atopic dermatitis. Allergol Int. 2017;66(4):539-44.

  27. Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician. 2014;90(4):229-35.

  28. Stevens DL, Bryant AE. Streptococcus pyogenes Impetigo, Erysipelas, and Cellulitis. In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes: Basic Biology to Clinical Manifestations. Oklahoma City (OK): University of Oklahoma Health Sciences Center © The University of Oklahoma Health Sciences Center.; 2022.

  29. Lin HS, Lin PT, Tsai YS, Wang SH, Chi CC. Interventions for bacterial folliculitis and boils (furuncles and carbuncles). Cochrane Database Syst Rev. 2021;2(2):Cd013099.

  30. Läkemedelsbehandling av borreliainfektion – ny rekommendation. Information från Läkemedelsverket. 2009;20(4):12-7.

  31. Nadelman RB. Erythema migrans. Infect Dis Clin North Am. 2015;29(2):211-39.

  32. Ross Russell AL, Dryden MS, Pinto AA, Lovett JK. Lyme disease: diagnosis and management. Pract Neurol. 2018;18(6):455-64.

  33. Zajkowska J, Czupryna P, Pancewicz SA, Kondrusik M, Moniuszko A. Acrodermatitis chronica atrophicans. Lancet Infect Dis. 2011;11(10):800.

  34. Zhu S, Viejo-Borbolla A. Pathogenesis and virulence of herpes simplex virus. Virulence. 2021;12(1):2670-702.

  35. Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother. 2002;46(7):2238-43.

  36. Li Q, Chen N, Yang J, Zhou M, Zhou D, Zhang Q, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2009(2):Cd006866.

  37. El-Gohary M, van Zuuren EJ, Fedorowicz Z, Burgess H, Doney L, Stuart B, et al. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev. 2014(8):Cd009992.

  38. Kreijkamp-Kaspers S, Hawke K, Guo L, Kerin G, Bell-Syer SE, Magin P, et al. Oral antifungal medication for toenail onychomycosis. Cochrane Database Syst Rev. 2017;7(7):Cd010031.

  39. Lipner SR, Scher RK. Onychomycosis: Treatment and prevention of recurrence. J Am Acad Dermatol. 2019;80(4):853-67.

  40. Panthagani AP, Tidman MJ. Diagnosis directs treatment in fungal infections of the skin. Practitioner. 2015;259(1786):25-9, 3.

  41. Zampella JG, Kwatra SG, Blanck J, Cohen B. Tinea in Tots: Cases and Literature Review of Oral Antifungal Treatment of Tinea Capitis in Children under 2 Years of Age. J Pediatr. 2017;183:12-8.e3.

  42. Thomas C, Coates SJ, Engelman D, Chosidow O, Chang AY. Ectoparasites: Scabies. J Am Acad Dermatol. 2020;82(3):533-48.

  43. Coates SJ, Thomas C, Chosidow O, Engelman D, Chang AY. Ectoparasites: Pediculosis and tungiasis. J Am Acad Dermatol. 2020;82(3):551-69.

  44. Behandling av huvudlöss – behandlingsrekommendation. Information från Läkemedelsverket. 2019;30(3):1-5.

  45. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol. 2001;137(6):765-70.

  46. Cardones AR, Hall RP, 3rd. Management of dermatitis herpetiformis. Immunol Allergy Clin North Am. 2012;32(2):275-81, vi-vii.

  47. Christensen OB, Hindsén M, Svensson A. Natural history of dermatitis herpetiformis in southern Sweden. Dermatologica. 1986;173(6):271-7.

  48. Ermacora E, Prampolini L, Tribbia G, Pezzoli G, Gelmetti C, Cucchi G, et al. Long-term follow-up of dermatitis herpetiformis in children. J Am Acad Dermatol. 1986;15(1):24-30.

  49. Mobacken H, Kastrup W, Nilsson LA. Incidence and prevalence of dermatitis herpetiformis in western Sweden. Acta Derm Venereol. 1984;64(5):400-4.

  50. Mansikka E, Hervonen K, Kaukinen K, Ilus T, Oksanen P, Lindfors K, et al. Gluten Challenge Induces Skin and Small Bowel Relapse in Long-Term Gluten-Free Diet-Treated Dermatitis Herpetiformis. J Invest Dermatol. 2019;139(10):2108-14.

  51. Burfield L, Rutter KJ, Thompson B, Marjanovic EJ, Neale RE, Rhodes LE. Systematic review of the prevalence and incidence of the photodermatoses with meta-analysis of the prevalence of polymorphic light eruption. J Eur Acad Dermatol Venereol. 2023;37(3):511-20.

  52. Gruber-Wackernagel A, Byrne SN, Wolf P. Polymorphous light eruption: clinic aspects and pathogenesis. Dermatol Clin. 2014;32(3):315-34, viii.

  53. Svenska Sällskapet för Dermatologi och Venereologi (SSDV). Riktlinjer för handläggning av primär hyperhidros inom dermatologi och venereologi. mars 2022.

  54. Barton VR, Toussi A, Awasthi S, Kiuru M. Treatment of pediatric alopecia areata: A systematic review. J Am Acad Dermatol. 2022;86(6):1318-34.

  55. Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol. 2017;76(1):22-8.

  56. Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients. J Am Acad Dermatol. 2018;78(2):403-4.e1.

  57. König A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology. 1999;198(3):261-4.

  58. Pink AE, Simpson MA, Desai N, Trembath RC, Barker JNW. γ-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis. J Invest Dermatol. 2013;133(3):601-7.

  59. Porter ML, Kimball AB. Comorbidities of hidradenitis suppurativa. Semin Cutan Med Surg. 2017;36(2):55-7.

  60. Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-44.

  61. Le Cleach L, Chosidow O. Clinical practice. Lichen planus. N Engl J Med. 2012;366(8):723-32.

  62. Tziotzios C, Brier T, Lee JYW, Saito R, Hsu CK, Bhargava K, et al. Lichen planus and lichenoid dermatoses: Conventional and emerging therapeutic strategies. J Am Acad Dermatol. 2018;79(5):807-18.

  63. Kirtschig G, Becker K, Günthert A, Jasaitiene D, Cooper S, Chi CC, et al. Evidence-based (S3) Guideline on (anogenital) Lichen sclerosus. J Eur Acad Dermatol Venereol. 2015;29(10):e1-43.

  64. Lewis FM, Tatnall FM, Velangi SS, Bunker CB, Kumar A, Brackenbury F, et al. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. Br J Dermatol. 2018;178(4):839-53.

  65. Joshi TP, Duvic M. Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options. Am J Clin Dermatol. 2022;23(1):37-50.

  66. Piette EW, Rosenbach M. Granuloma annulare: Pathogenesis, disease associations and triggers, and therapeutic options. J Am Acad Dermatol. 2016;75(3):467-79.

  67. Thornsberry LA, English JC, 3rd. Etiology, diagnosis, and therapeutic management of granuloma annulare: an update. Am J Clin Dermatol. 2013;14(4):279-90.

  68. Hwang S, Schwartz RA. Keratosis pilaris: a common follicular hyperkeratosis. Cutis. 2008;82(3):177-80.

  69. Kodali N, Patel VM, Schwartz RA. Keratosis pilaris: an update and approach to management. Ital J Dermatol Venerol. 2023;158(3):217-23.

Föregående sida
Keratosis pilaris

Nästa sida
Tillbaka till kapitlets första sida